Five things for pharma marketers to know: Thursday, September 17, 2015
Photo credit: Ryan/Creative Commons
A new analysis of old data concluded that GlaxoSmithKline's antidepressant Paxil is not a safe or effective treatment for teenagers, according to the BMJ. There has been concern among some in the medical community that people taking Paxil or withdrawing from it have committed violent acts and the new analysis will likely open the door for journals to publish different interpretations of the same data, The New York Times reported.
Three FDA reviewers recommended against approving Addyi, the controversial female-libido pill, over concerns about side effects and marginal clinical benefits. The type of disagreement isn't typical but can happen, an analyst told Bloomberg Business. The drug was twice rejected before the FDA approved it mid-August. Valeant acquired the drug's maker, Sprout, for $1 billion the day after the drug was approved.
The Department of Health and Human Services formed a public-private partnership with AstraZeneca to develop new antibiotics. The organizations will also seek to develop treatments for illnesses caused by bioterrorism agents.
Perrigo urged its shareholders to reject Mylan's latest takeover bid, MarketWatch reported. Perrigo's management and board have already turned down Mylan's offers.
Philips Healthcare, Salesforce and a Netherlands-based hospital developed a mobile app and online community for type-1 diabetes patients and their healthcare providers. The new system pools data from electronic medical records, personal health devices like glucose meters and activity monitors and self-reported patient data.